Incyte Corp (INCY) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Incyte Corp, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track INCY live on Mooboard →

This week2

  • Sep 28, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    INCB099280 · Phase 2 · Cutaneous Squamous Cell Carcinoma
    NCT05888844: A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma. Primary completion 2026-09-28 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    INCB099280 · Phase 2 · Advanced Solid Tumor
    NCT05879822: A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Next 30 days4

  • Oct 9, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    Ruxolitinib Cream · Phase 3 · Hidradenitis Suppurativa
    NCT06959225: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1). Primary completion 2026-10-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 9, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    Ruxolitinib Cream · Phase 3 · Hidradenitis Suppurativa
    NCT06958211: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2). Primary completion 2026-10-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 19, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    Povorcitinib · Phase 3 · Prurigo Nodularis
    NCT06516952: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 19, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    Povorcitinib · Phase 3 · Prurigo Nodularis
    NCT06516965: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days2

  • Nov 5, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    Parsaclisib · Phase 2 · B-Cell Malignancies
    NCT04509700: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465). Primary completion 2026-11-05 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 20, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    povorcitinib · Phase 2 · Moderate to Severe Asthma
    NCT05851443: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. Primary completion 2026-11-20 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later17

  • Dec 26, 2026
    Incyte Corp(INCY)Phase 2/3 readout
    Povorcitinib · Phase 3 · Hidradenitis Suppurativa (HS)
    NCT06212999: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa. Primary completion 2026-12-26 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 6, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    INCA034176 · Phase 1 / Phase 2 · Chronic Graft-versus-host-disease
    NCT06843408: A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD. Primary completion 2027-01-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 27, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    INCB123667 · Phase 2 · Ovarian Cancer
    NCT07023627: A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression. Primary completion 2027-04-27 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 30, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    Ruxolitinib Cream · Phase 3 · NonSegmental Vitiligo
    NCT06804811: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo. Primary completion 2027-04-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 1, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    Axatilimab · Phase 2 · Chronic Graft-versus-host-disease
    NCT06388564: A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease. Primary completion 2027-06-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 30, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    INCB000928 · Phase 2 · Fibrodysplasia Ossificans Progressiva (FOP)
    NCT05090891: To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva. Primary completion 2027-07-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 29, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    Tafasitamab · Phase 2 · Hematologic Malignancies
    NCT06465433: Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab. Primary completion 2027-08-29 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 23, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    INCA000585 · Phase 2 · Immune Thrombocytopenia
    NCT07104565: Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders. Primary completion 2027-09-23 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 28, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    INCA034176 · Phase 3 · Chronic Graft-versus-host-disease
    NCT06585774: A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease. Primary completion 2027-09-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2027
    Incyte Corp(INCY)Phase 2/3 readout
    Ruxolitinib · Phase 2 · Pancreatic Cancer; Colorectal Cancer (CRC)
    NCT02955940: An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib. Primary completion 2027-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 1, 2028
    Incyte Corp(INCY)Phase 2/3 readout
    Ponatinib · Phase 1 / Phase 2 · Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia
    NCT03934372: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors. Primary completion 2028-02-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 28, 2028
    Incyte Corp(INCY)Phase 2/3 readout
    povorcitinib · Phase 3 · Hidradenitis Suppurativa (HS)
    NCT06855498: Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib. Primary completion 2028-02-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 25, 2028
    Incyte Corp(INCY)Phase 2/3 readout
    Povorcitinib · Phase 2 · Hidradenitis Suppurativa (HS)
    NCT07213973: Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa. Primary completion 2028-03-25 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2028
    Incyte Corp(INCY)Phase 2/3 readout
    INCA034176 · Phase 3 · Chronic Graft-versus-host-disease
    NCT06821542: A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy. Primary completion 2028-05-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 5, 2028
    Incyte Corp(INCY)Phase 2/3 readout
    Ruxolitinib Cream · Phase 3 · NonSegmental Vitiligo
    NCT06548360: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo. Primary completion 2028-06-05 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 15, 2028
    Incyte Corp(INCY)Phase 2/3 readout
    INCB161734 · Phase 3 · Solid Tumors
    NCT07522073: A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Primary completion 2028-09-15 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 15, 2028
    Incyte Corp(INCY)Phase 2/3 readout
    INCB123667 · Phase 3 · Ovarian Cancer
    NCT07214779: Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression. Primary completion 2028-11-15 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Incyte Corp has moved — past-year price reactions

How binary is INCY? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.1%
typical day (1Y)
0
±10% days
33.3%
annualized vol
249
trading days
Largest single-day moves
  • +9.3%2026-07-28no matched headline
  • +8.7%2025-11-03no matched headline
  • -8.2%2026-02-10no matched headline
  • +6.2%2026-06-03no matched headline
  • -6%2026-06-15no matched headline
  • +5.8%2026-06-26no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Incyte Corp — active clinical pipeline

Incyte Corp's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

24 assets49 programsPh1 16Ph2 18Ph3 15
AreasOncologyAutoimmuneImmunologyCardiovascularOther
PovorcitinibImmunology
Phase 1
Immunology
Phase 2
Hidradenitis Suppurativa (HS)Moderate to Severe Asthma
Phase 3
Hidradenitis Suppurativa (HS) (2)NonSegmental Vitiligo (2)Prurigo Nodularis (2)
tafasitamabOncology · CD19
Phase 2
Diffuse Large B Cell LymphomaHematologic MalignanciesNon Hodgkins Lymphoma
Phase 3
Diffuse Large B-cell LymphomaFollicular LymphomaLarge B-Cell Lymphoma
INCB123667Oncology
Phase 1
Hepatic InsufficiencyRenal Impairment
Phase 2
Ovarian Cancer
Phase 3
Ovarian Cancer (2)
INCA033989Cardiovascular
Phase 1
CardiovascularMyeloproliferative Neoplasms (2)
Phase 3
Essential Thrombocythemia
INCA33890Oncology
Phase 1
Solid Tumors
Phase 2
CRC (Colorectal Cancer)
Phase 3
CRC (Colorectal Cancer)
INCB161734Oncology
Phase 1
OncologySolid Tumors
Phase 3
Solid Tumors
Ruxolitinib CreamImmunology
Phase 1
Hidradenitis Suppurativa
Phase 3
Hidradenitis Suppurativa (2)NonSegmental Vitiligo (2)
INCA034176Immunology
Phase 2
Chronic Graft-versus-host-disease (2)
Phase 3
Chronic Graft-versus-host-disease (3)
RuxolitinibImmunology
Phase 2
Pancreatic Cancer
Phase 3
Atopic Dermatitis
Tacrolimus (Tac)Immunology
Phase 3
Graft-versus-host Disease (GVHD)
INCB000928Other
Phase 2
AnemiaFibrodysplasia Ossificans Progressiva (FOP)
INCB099280Oncology
Phase 2
Advanced Solid TumorCutaneous Squamous Cell Carcinoma
AxatilimabImmunology · CSF1R
Phase 2
Chronic Graft-versus-host-disease
INCA000585Autoimmune
Phase 2
Immune Thrombocytopenia
ParsaclisibOncology · PIK3CD
Phase 2
B-Cell Malignancies
PonatinibOncology
Phase 2
Acute Myeloid Leukemia
RetifanlimabOncology · PD-1
Phase 2
Head and Neck Cancer
INCA035784Oncology
Phase 1
Myeloproliferative Neoplasms
INCA036873Oncology
Phase 1
Solid Tumors
INCA036978Oncology
Phase 1
Myeloproliferative Neoplasms
INCB0123667Oncology
Phase 1
Solid Tumors
INCB057643Oncology
Phase 1
Myelofibrosis
INCB160058Oncology
Phase 1
Myeloproliferative Neoplasms
INCB186748Oncology
Phase 1
Solid Tumors

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.